Home
Live Updates
New Human Biomarker Findings Support Mechanism of Action of Kerendia® (finerenone) in Patients with Chronic Kidney Disease Associated with Type 2 Diabetes : vimarsana.com
New Human Biomarker Findings Support Mechanism of Action of Kerendia® (finerenone) in Patients with Chronic Kidney Disease Associated with Type 2 Diabetes
WHIPPANY, N.J.--(BUSINESS WIRE)--Nov 2, 2023--
Related Keywords
United States ,
American ,
Semin Nephrol ,
Christian Rommel ,
American Kidney Fund ,
National Diabetes Statistics ,
Head Of Research ,
National Institute Of Diabetes ,
Facebook ,
American Diabetes Association ,
Bayer Healthcare Pharmaceuticals Inc ,
Twitter ,
National Institutes Of Health ,
Clinical Trials Program ,
American Society Of Nephrology ,
American Association Of Clinical Endocrinology ,
Centers For Disease ,
American Society ,
Kidney Week ,
Executive Committee ,
Kerendia Phase ,
American Association ,
Clinical Endocrinology ,
Kidney Disease ,
Improving Global Outcomes ,
Prescribing Informationfor ,
Trials Program ,
Chronic Kidney Disease Associated ,
Bayer Healthcare Pharmaceuticals ,
Rev Dis ,
Diabetes Statistics Report ,
Its Burden ,
Disease Control ,
Accessed July ,
Accessed May ,
States Renal Data ,
National Institutes ,
National Institute ,
Kidney Diseases ,
Media Contact ,
Business Wire ,
Region ,
vimarsana.com © 2020. All Rights Reserved.